Effects of renal replacement therapy on plasma lipoprotein(a) levels

American Journal of Nephrology

Volumn 28, Issue 3, 2008, Pages 361-365

  Rosas, Sylvia ^a,c   Joffe, Marshall ^a   Wolfe, Megan ^a   Brayman, Kenneth ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c 111 CRB ^*  (United States)

Author keywords

Cardiovascular risk factors; Clinical epidemiology; Lipoprotein(a); Renal transplantation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CREATININE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; THERAPY EFFECT;

ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 41849143389     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112225     Document Type: Article

References (36)

1. Rader D, Brewer HB Jr: Lipoprotein(a) - clinical approach to a unique atherogenic lipoprotein. JAMA 1992;267:1109-1112.
2. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993;91:443-447.
3. Rader D, Cain W, Ikewaki K, et al: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-2763.
4. Rader D, Mann WA, Cain W, et al: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995;95:1403-1408.
5. Bostom AG, Cupples LA, Jenner JL, et al: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996;276:544-548.
6. Rosengreen A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein(a) and coronary heart disease: a prospective case-control study in the general population sample of middle-aged men. BMJ 1990;301:1248-1251.
7. Schaefer EJ, Lamon-Fava S, Jenner JL, et al: Lipoprotein(a) levels and risk of coronary heart disease in men - The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
8. Jauhiainen M, Koskinen P, Ehnholm C, et al: Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
9. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-2199.
10. Demant T, Seeberg K, Bedynek A, Seidel D: The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis 2001;157:325-339.
11. Jenner JL, Seman LJ, Millar JS, et al: The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a) in human beings. Metabolism 2005;54:361-369.
12. Barbagallo CM, Averna MR, Sparacino V, et al: Lipoprotein(a) levels in end-stage renal failure and renal transplantation. Nephron 1993;64:560-564.
13. Bostom AG, Shemin D, Lapane KL, et al: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996;125:91-101.
14. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987;33:721.
15. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-482.
16. Cressman MD, Hoogwerf BJ, Schreiber MJ, Cosentino FA: Lipid abnormalities and endstage renal disease: implications for atherosclerotic cardiovascular disease? Miner Electrolyte Metab 1993;19:180-185.
17. Kronenberg F, Konig P, Neyer U, et al: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-120.
18. Lye WC, Hughes K, Leong SO, Tan CC, Lee EJC: Abnormal lipoprotein(a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 1995;27:977-978.
19. Kronenberg F, Trenkwalder E, Lingenhel A, et al: Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997;38:1755-1763.
20. Azrolan N, Brown CD, Thomas L, et al: Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Arterioscler Thromb 1994;14:1393-1398.
21. Sechi LA, Zingaro L, De Carli S, et al: Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998;129:457-461.
22. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC: Serum Lp(a) levels in patients with moderate renal failure. Nephron 1998;79:367-368.
23. Dieplinger H, Lackner C, Kronenberg F, et al: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401.
24. Kerschdorfer L, Konig P, Neyer U, et al: Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 1999;144:381-391.
25. Von Ahsen N, Helmhold M, Eisenhauer T, Armstrong VW, Oellerich M: Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur J Clin Invest 1996;26:668-675.
26. Black IW, Wilcken DE: Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353-357.
27. Kronenberg F, Konig P, Lhotta K, et al: Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994;14:1399-1404.
28. Hohage H, Artt M, Bruckner D, Dietl K, Zidek W, Spieker C: Effects of cyclosporin A and FK-506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant 1997;11:225-230.
29. Brown JH, Murphy BG, Douglas AF, et al: Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 1997;75:277-282.
30. Brown JH, Anwar N, Short CD, et al: Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993;8:863-867.
31. Webb AT, Plant M, Reaveley DA, et al: Lipid and lipoprotein(a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992;7:636-641.
32. Hilbrands L, Demacker P, Hoitsma A, Stalenhoef A, Koene R: The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995;5:2073-2081.
33. Webb AT, Reavely DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993;341:268-270.
34. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK-506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years [erratum appears in Transplantation 2002;73:1370]. Transplantation 2002;73:775-782.
35. Frischmann ME, Kronenberg F, Trenkwalder E, et al: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007;71:1036-1043.
36. Diop ME, Viron B, Bailleul S, et al: Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane:a 2-year follow-up study. Clin Nephrol 2000;54:210-217.